Literature DB >> 8086012

beta-Amyloid protein-induced Alzheimer's disease animal model.

A Nitta1, A Itoh, T Hasegawa, T Nabeshima.   

Abstract

To investigate the toxicity of beta-amyloid protein which consisted of senile plaques of Alzheimer's disease (AD), this was infused into cerebral ventricle for 14 days by using mini-osmotic pump. The performance of the water maze task in beta-amyloid protein-treated rats was impaired. Choline acetyltransferase activity significantly decreased in the frontal cortex and hippocampus. These results suggest that the deposition of beta-amyloid protein in the brain is related to the impairment of learning and cholinergic neuronal degeneration, and that beta-amyloid protein-treated rats could be used as an animal model for AD.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8086012     DOI: 10.1016/0304-3940(94)90239-9

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  63 in total

1.  Effects of synaptic plasticity regulated by 17beta-estradiol on learning and memory in rats with Alzheimer's disease.

Authors:  Xiu-Li Shang; Jiu-Han Zhao; Yun-Peng Cao; Yi-Xue Xue
Journal:  Neurosci Bull       Date:  2010-04       Impact factor: 5.203

2.  Studies of the effects of fragment (25-35) of beta-amyloid peptide on the behavior of rats in a radial maze.

Authors:  M Yu Stepanichev; Yu V Moiseeva; N A Lazareva; N V Gulyaeva
Journal:  Neurosci Behav Physiol       Date:  2005-06

3.  Protection against beta-amyloid peptide toxicity in vivo with long-term administration of ferulic acid.

Authors:  J J Yan; J Y Cho; H S Kim; K L Kim; J S Jung; S O Huh; H W Suh; Y H Kim; D K Song
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

4.  Studies of the effects of central administration of beta-amyloid peptide (25-35): pathomorphological changes in the Hippocampus and impairment of spatial memory.

Authors:  M Yu Stepanichev; I M Zdobnova; I I Zarubenko; N A Lazareva; N V Gulyaeva
Journal:  Neurosci Behav Physiol       Date:  2006-01

5.  T-817MA, a neurotrophic agent, ameliorates the deficits in adult neurogenesis and spatial memory in rats infused i.c.v. with amyloid-beta peptide.

Authors:  Tatsuo Kimura; Phuong Thi Hong Nguyen; Son Anh Ho; Anh Hai Tran; Taketoshi Ono; Hisao Nishijo
Journal:  Br J Pharmacol       Date:  2009-04-03       Impact factor: 8.739

Review 6.  Alzheimer's disease amyloid beta-protein and synaptic function.

Authors:  Tomas Ondrejcak; Igor Klyubin; Neng-Wei Hu; Andrew E Barry; William K Cullen; Michael J Rowan
Journal:  Neuromolecular Med       Date:  2009-09-16       Impact factor: 3.843

7.  Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-β peptide in mice.

Authors:  Yoko Furukawa-Hibi; Tursun Alkam; Atsumi Nitta; Akihiro Matsuyama; Hiroyuki Mizoguchi; Kazuhiko Suzuki; Saliha Moussaoui; Qian-Sheng Yu; Nigel H Greig; Taku Nagai; Kiyofumi Yamada
Journal:  Behav Brain Res       Date:  2011-07-27       Impact factor: 3.332

8.  Beta-amyloid prevents excitotoxicity via recruitment of glial glutamate transporters.

Authors:  Atsushi Baba; Kazuhiko Mitsumori; Maki K Yamada; Nobuyoshi Nishiyama; Norio Matsuki; Yuji Ikegaya
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-09-04       Impact factor: 3.000

Review 9.  What can rodent models tell us about cognitive decline in Alzheimer's disease?

Authors:  Sabrina Davis; Serge Laroche
Journal:  Mol Neurobiol       Date:  2003-06       Impact factor: 5.590

Review 10.  Behavioral assays with mouse models of Alzheimer's disease: practical considerations and guidelines.

Authors:  Daniela Puzzo; Linda Lee; Agostino Palmeri; Giorgio Calabrese; Ottavio Arancio
Journal:  Biochem Pharmacol       Date:  2014-01-21       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.